ARCHIVES

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Uncertainty Lingers After NCI Meeting With Army; Activists Offer Advice

November 6, 1992

Neurocognitive Deficits Affect Future Adult Employment

September 30, 2011

FDA Approves Ribavirin Phase 102 Trials

October 30, 1987

Dramatic Increase In Third World Cancer Rates May Face National, International Organizations: Murphy

September 17, 1982

New Screening Tool Helps GP ID Hereditary BC Risk

October 27, 2006

In Brief: Einhorn Named Karnofsky Lecturer; Consensus Conferences On Colon, Breast Cancer Planned

February 2, 1990